GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.